News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2009 Archives

Dec 14, 2009

Nektar Therapeutics announced today that Dennis Winger has been appointed to serve on its board of directors. Winger is a highly-respected biopharmaceutical industry leader with over 35 years of...

More
Nov 30, 2009

Nektar Therapeutics today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Dr. Masuoka will report directly to Nektar's President and Chief...

More
Nov 4, 2009

Nektar Therapeutics today reported its financial results for the third quarter ended September 30, 2009. Net loss for the quarter ended September 30, 2009 improved to $31.0 million or $0.33 per...

More
Oct 29, 2009

Nektar Therapeutics will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial markets. Howard...

More
Oct 28, 2009

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's...

More
Oct 10, 2009

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix,...

More
Sep 22, 2009
Nektar commences second stage of Phase 2 clinical trial of NKTR-102 in platinum-resistant ovarian cancer ahead of schedule

Nektar Therapeutics presented favorable data today on lead oncology program, NKTR-102, demonstrating encouraging Phase 1 and preclinical anti-tumor activity of the investigational compound in...

More
Sep 21, 2009

Nektar Therapeutics announced that it will be hosting a conference call to discuss today's announcement of a new partnership for NKTR-118 and NKTR-119. The call will begin at 8:30 a.m. Eastern...

More
Sep 21, 2009

AstraZeneca and Nektar Therapeutics announced today that they have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational...

More
Sep 18, 2009

Nektar Therapeutics is scheduled to present at the upcoming UBS 2009 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September 22, 2009 at 10:30 a.m. Eastern time....

More
Sep 13, 2009
Oral Tablet Clinical Pharmacokinetic Data Presented at 38th Annual American College of Clinical Pharmacology (ACCP) Meeting in San Antonio

Nektar Therapeutics presented clinical study data today demonstrating that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant...

More
Aug 4, 2009

Nektar Therapeutics today reported its financial results for the second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to...

More
Jul 31, 2009

Nektar Therapeutics is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York City on Wednesday, August 5,...

More
Jul 31, 2009

Nektar Therapeutics will announce its financial results for the second quarter ended June 30, 2009 on Tuesday, August 4, 2009, after the close of U.S.-based financial markets. Howard Robin,...

More
Jun 9, 2009

Nektar Therapeutics today announced the promotion of Lorianne Masuoka, M.D. to the position of Chief Medical Officer. Dr. Masuoka reports to Nektar's Senior Vice President, Drug Development and...

More
May 14, 2009
Nektar Advanced Polymer Conjugate Technology Used in Cimzia® Through Exclusive Nektar-UCB Collaboration

Nektar Therapeutics confirmed today UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol), the only PEGylated anti-TNFa (Tumor Necrosis...

More
May 12, 2009

Nektar Therapeutics is scheduled to present at the upcoming Deutsche Bank 34th Annual Health Care Conference in Boston at the Boston InterContinental Hotel on Monday, May 18, 2009 at 1:45 p.m....

More
May 6, 2009

Nektar Therapeutics today reported its financial results for the first quarter ended March 31, 2009. Net loss for the quarter ended March 31, 2009 was $31.8 million or $0.34 per share, compared to...

More
Apr 29, 2009

Nektar Therapeutics will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial markets. Howard Robin,...

More
Apr 22, 2009

Nektar Therapeutics presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior...

More
Mar 10, 2009

Nektar Therapeutics' President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Cowen and Company 29th Annual Healthcare Conference in Boston at the Boston...

More
Mar 2, 2009
Highly Statistically Significant Results Achieved at Two Dose Levels with No Reversal of Analgesia

Nektar Therapeutics announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation (OIC)....

More
Feb 24, 2009

Nektar Therapeutics today reported its financial results for the fourth quarter and year ended December 31, 2008. "2008 was a transformational year for Nektar," said Howard W. Robin, President and...

More
Feb 17, 2009

Nektar Therapeutics announced today that the first patients have been dosed in a Phase 1 dose-escalation study of NKTR-105, a novel PEGylated form of docetaxel. The Phase 1 study will assess the...

More
Feb 11, 2009

Nektar Therapeutics will announce its financial results for the fourth quarter and year ended December 31, 2008 on Wednesday, February 25, 2009, after the close of U.S.-based financial markets....

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide